Out of the Red and into the Black: John McCamant on Investment in Jutia Group We have seen Celgene Corp. (CELG:NASDAQ) target multiple myeloma with Revlimid (lenalidomide), and we've seen other drugs in this space, such as Genentech/Roche Holding AG's (RHHBY:OTCQX) Rituxan (rituximab) targeting B-cell lymphomas. |
